Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal PIX 301 EXTEND trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14 of 70 patients (20.0%) for the pixantrone arm compared to four of 70 patients (5.7%) for the standard chemotherapy arm, p=0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission while on study.

The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.

In April 2009, CTI began a rolling submission of a New Drug Application (the "NDA") with the FDA for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... Bionik Laboratories, Inc., a Toronto ... accredited investors of units consisting of its common stock ... million. Shares of the Company,s common stock will continue ... symbol "DWTPD" until FINRA,s approval of the ticker "BNKL." ...
(Date:2/27/2015)... , Feb. 27, 2015  Two mass ... in applications as their effectiveness is established, ... Information.  Kalorama Information says that while mass ... most powerful tool in proteomic biomarker discovery ... through its traditional techniques has struggled to ...
(Date:2/26/2015)... 27, 2015 RnRMarketResearch.com adds ... research report to its store. This report p ... pipeline. The report "Corneal Ulcers - Pipeline Review, ... development for Corneal Ulcers. Corneal Ulcers are primarily ... infections, viral infections & fungal infections. The symptoms ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
... , PORTLAND, Ore. , Feb. 8 ... enhance the use of localized content by sales teams. Together, ... time for translated content to reach the hands of global ... accelerate the sales cycle. This combination gives the sales person ...
... , ST. LOUIS , Feb. 8 Stereotaxis ... Stereotaxis Magnetic Navigation System in Taiwan at Cheng-Hsin General ... Opening event on January 26 that received wide coverage ... performed using Stereotaxis at the hospital. , "All too often during ...
Cached Medicine Technology:Prolifiq and viaLanguage Announce Partnership: Accelerate the Use of Localized Content by Sales Teams 2Prolifiq and viaLanguage Announce Partnership: Accelerate the Use of Localized Content by Sales Teams 3Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 On February ... “The Real Liquid Botox ,” that details the development ... that is working its way through FDA trials. For those ... cream is very attractive. Of course, if the drug ... prescription at a physician’s office. (see: goo.gl/PQvQwk) , “As the ...
(Date:2/27/2015)... 27, 2015 The Dawn Greene Hospice, a ... Walsh Home (MMW) on the Upper East Side, was officially ... New York, His Eminence Timothy Michael Cardinal Dolan. , Thomas ... of Directors and a member of the ArchCare Board of ... William O’Brien, O.Carm, executive director of MMW, and Christina McInerney, ...
(Date:2/27/2015)... February 27, 2015 The UC Davis ... expertise have made it a beacon of hope for ... has been acknowledged by the national society committed to ... Huntington’s Disease Society of America — as a Level ... acknowledgement recognizes the center’s service to over 300 families ...
(Date:2/27/2015)... IL (PRWEB) February 27, 2015 ... Output Medical to advance the development of an ... The new solution is being developed in direct ... offer only 73% accuracy and error margins with ... automate error-free output measurement and provide trending data ...
(Date:2/27/2015)... "After studying the benefits and risks to mom ... bifida repair may outweigh the risks for those moms who ... Fetal Care Institute Director Dr. Mike Vlastos, who ... "The goal of the study is to gain an understanding ... unborn babies." , Studies have shown that mothers with an ...
Breaking Medicine News(10 mins):Health News:Is Topical Botox the Next Big Thing? 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 2Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 3
... REGISTER NOW , , CHICAGO, July 9 ... of Chicago, the American Cancer Society Charity Runner Team is ... , , , "The Society is thrilled to ... Marathon," said Alison Tibbits, project manager, fundraising resources, American Cancer ...
... July 9 /PRNewswire-USNewswire/ -- Skyrocketing prescription drug prices are ... to cut back on the basics, like food and utilities, in ... survey, as brand name drugs see record price increases, the majority ... to pay for their medications in the coming year. ...
... Corporation (OTC Bulletin Board: CONX), a worldwide developer and ... AspirinWorks(R) Test at the XXII Congress and the 55th ... International Society on Thrombosis and Haemostasis (ISTH). The ISTH ... Boston Convention & Exhibition Center. , , Corgenix ...
... Specialty care physicians can improve the health of ... providing e-consultations and treatment plan recommendations with primary care ... in the British Medical Journal. , ... demonstrated that specialists can take a more active role ...
... of SEIU UHW will hold a news conference at 3 p.m. ... to release newly obtained information showing that ousted union President Sal ... attorney that some of the actions may be illegal but took ... to cover them up. , , The documents detailing ...
... July 9 Today, Bayer HealthCare Pharmaceuticals launched the ... make infusion of recombinant factor VIII easier for both ... The centerpiece of the program is an adjustable cuff ... to practice the technique of self-injection without actually infusing ...
Cached Medicine News:Health News:Calling All Runners: Join the Fight Against Cancer 2Health News:High Rx Costs Hammering Illinois' 50+ Population 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting 3Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 2Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 3Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 4Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 3Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 4Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 5
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: